![[Bio USA] Samsung Biologics expands strategic focus to top 40 global pharma](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F06%2F19%2Fnews-p.v1.20250619.f34cb4b31f824ab69474a7e12b02477a_T1.jpg&w=3840&q=100)
[Bio USA] Samsung Biologics expands strategic focus to top 40 global pharma
"Today, we serve more than 130 clients, including 17 of the world's top 20 pharmaceutical companies, with a batch success rate exceeding 99 percent and 359 regulatory approvals from global health authorities," said Kevin Sharp, executive vice president and head of sales and operations at Samsung Biologics, during a press conference held on the sidelines of Bio USA.
Samsung Biologics has been establishing local offices in strategic regions and maintaining seamless collaboration with its global headquarters in Songdo.
'We already operate sales offices in New Jersey and Boston through our US subsidiary, and opened a new office in Tokyo earlier this year to better contact the top 40 pharma companies."
Samsung Biologics has also built core competencies in advanced and emerging modalities — including messenger mRNA, antibody drug conjugates and competetive genetic therapies. Looking ahead, the company plans to begin manufacturing ADC drug products and pre-filled syringes by 2027.
Further expanding its value chain integration, Samsung Biologics is now moving upstream into contract research services. This includes the launch of its first organoid-based drug screening platform, Samsung Organoids, a move that marks its formal entry into contract research.
At a related press briefing on Tuesday, Lee Sang-myung, vice president and head of Business Strategy at Samsung Biologics, emphasized the promise of organoid technology in revolutionizing drug development.
'Organoids are rapidly transforming the drug development landscape,' he said. 'With up to 85 percent physiological similarity to human patients, they provide a more accurate, scalable and cost-effective alternative to traditional animal testing.'
According to market intelligence firm Research and Markets and others, the global patient-derived organoid market is valued at $1 billion in 2024 and is projected to grow to $3.3 billion by 2030, with a compound annual growth rate of 22 percent. Such rapid growth is being driven in part by the FDA's push to reduce reliance on animal testing and to promote ethically sound alternatives.
Samsung Biologics' organoid strategy is further bolstered by an exclusive partnership with Samsung Medical Center, recently ranked No. 3 globally in cancer care by Newsweek in 2025. The collaboration merges SMC's vast clinical dataset drawn from over 4.5 million patients, with Samsung Biologics' capabilities in manufacturing and data analytics, enabling the generation of highly precise drug efficacy data.
'The launch of Samsung Organoids marks a strategic inflection point for us,' Lee noted. 'Having evolved from a pure CMO in 2011 to a CDO in 2018, we are now transitioning into a fully integrated CRDMO — adding research and discovery to our core manufacturing strengths.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
18 hours ago
- Korea Herald
Samsung chief doubles down on home investment plans amid US expansion
Samsung Electronics Chair Lee Jae-yong has put the spotlight back on the conglomerate's massive investment drive, reaffirming his pledge to expand domestic jobs and foster high-value-added industries. During a business roundtable hosted by President Lee Jae Myung at the presidential office in Seoul on Tuesday, he vowed to push ahead with a 360 trillion won ($257.4 billion) investment in new growth sectors alongside its large-scale US commitments. 'Separate from our investments in the US, we will continue to invest in Korea to create quality jobs and nurture high-value-added industries," Chair Lee said during the meeting. His remarks underscore Samsung's intent to stay the course on its previously announced domestic investment plans regardless of any forthcoming developments in US investment. In May 2022, coinciding with the inauguration of President Yoon Suk Yeol's administration, Samsung pledged a total of 450 trillion won over five years to bolster next-generation growth drivers such as semiconductors, biotechnology and artificial intelligence. Of that total, 80 percent, 360 trillion won, has been earmarked for domestic investment, marking a 40 percent increase from the company's prior investment plans. Samsung Electronics is currently investing 20 trillion won in its Giheung campus in Gyeonggi Province to build three semiconductor research fabs and a next-generation research and development facility covering 460,000 square meters. It is also expanding its Pyeongtaek campus to include advanced memory, foundry and system semiconductor fabs. In the long term, Samsung plans to invest an additional 360 trillion won through 2047 to establish the largest semiconductor cluster in Korea, spanning 7.28 million square meters in Yongin, Gyeonggi Province. The first production line is set to begin operations by 2030. In the biotech sector, Samsung Biologics recently completed construction of its fifth plant in Songdo-gu, Incheon, and is proceeding with the development of Plants six through eight. The company had previously announced a roadmap to invest 7.5 trillion won over 10 years to further expand its biologics business. Samsung's investment initiative also includes a goal to recruit 80,000 new employees over the five-year span. According to market research firm Korea CXO Institute, Samsung Electronics hired 10,960 new employees last year — a 20.11 percent increase from the previous year — with the majority expected to be domestic hires. Industry observers are watching closely for any further details Samsung may unveil regarding its domestic investment roadmap. 'Given the geopolitical uncertainties, Samsung is likely aiming to build a stable ecosystem for advanced industries at home,' said an industry source who requested anonymity. 'The conglomerate's continued domestic investment is likely to influence the capital allocation strategies of other major firms.' Meanwhile, the Samsung chief is scheduled to attend the upcoming Korea-US summit's business delegation from Sunday to Tuesday.
Korea Herald
28-07-2025
- Korea Herald
Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025
SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercialising first-in-class and/or best-in-class medicines for cancer, today announced that an abstract featuring the latest data from a Phase I/II study of the Claudin 18.2 antibody-drug conjugate (ADC), ATG-022, has been accepted for poster presentation at the 2025 European Society for Medical Oncology Annual Congress (ESMO 2025), taking place from October 17th to October 21st at the Messe Berlin in Berlin, Germany. Details of the Poster Presentation: ATG-022 (Claudin 18.2 antibody-drug conjugate) Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH) Abstract Number: 2907 Presentation Number: 2113P Date: October 19, 2025 About ATG-022 ATG-022 is an antibody-drug conjugate (ADC) designed to target CLDN18.2, a member of the Claudin family of cell adhesion molecules. Under normal conditions, Claudins are located within tight junctions between cells, forming a barrier to regulate cell permeability. However, in cancer, Claudins are aberrantly expressed on the cell surface due to changes in cell polarity. CLDN18.2 is frequently overexpressed in a range of primary malignant tumors, including gastric, esophageal, cholangiocarcinoma, and pancreatic cancers. The U.S. Food and Drug Administration (FDA) has awarded Orphan Drug Designations to ATG-022, for gastric and pancreatic cancers. Data from the ongoing CLINCH study demonstrated that ATG-022 delivers robust efficacy across all levels of CLDN18.2 expression in gastric cancer patients, including those with high, low, and ultra-low expression. This broad activity positions ATG-022 as a potential market leader, capable of addressing the largest patient population with CLDN18.2-positive tumors. Furthermore, the strong efficacy observed in patients with low CLDN18.2 expression suggests promise for treating other tumor types with similar expression profiles. About Antengene Antengene Corporation Limited ("Antengene", SEHK: is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders". Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets, with the NDA for XPOVIO ® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia. Forward-looking statements The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange. For more information, please contact:
Korea Herald
23-07-2025
- Korea Herald
Samsung Biologics reports second quarter 2025 financial results
INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: a leading contract development and manufacturing organization (CDMO), today announced its financial results for the second quarter of fiscal year 2025. "Our second quarter results demonstrate continued strong momentum across our business," said John Rim, CEO and President of Samsung Biologics. "With Plant 5 now fully operational, we are leveraging our manufacturing expertise and expanded capacity to deliver seamless, end-to-end CDMO services at scale. We have broadened our portfolio with advancements in antibody-drug conjugates (ADCs) and the launch of research services, Samsung Organoids, further reinforcing our ability to offer a wider range of innovative solutions to clients. Additionally, we are redefining digitalization in biomanufacturing, harnessing advanced digital tools to deliver greater transparency, speed, and value—setting new standards in the industry. These strategic initiatives will continue to strengthen our ability to accelerate client pipelines, while fostering enduring partnerships grounded in quality and operational excellence." SECOND QUARTER 2025 RESULTS Samsung Biologics posted consolidated revenue of KRW 1,289.9 billion and operating profit of KRW 475.6 billion in the second quarter of 2025. On a standalone basis, the company reported revenue of KRW 1,014.2 billion and operating profit of KRW 477.0 billion. The growth was buoyed by the full utilization of Plants 1 through 3 and the continued ramp-up of Plant 4. In the first half of 2025, standalone revenue surpassed KRW 2 trillion, reflecting consistent momentum across all manufacturing plants. Sales contract volume in the first half reached USD 2.4 billion, bringing up the cumulative value to USD 18.7 billion. BUSINESS UPDATES In April, Samsung Biologics added 180 kL of capacity with Plant 5 to better meet clients' manufacturing needs. The facility, equipped with advanced automation and digital systems, integrates best practices and features from existing plants to ensure consistent operations and the highest quality standards. The company also broadened its service offering with the launch of research services, Samsung Organoids, which utilizes patient-derived organoids to support drug discovery and development. Samsung Organoids enables precision screening to predict patient-specific drug responses and provides clients with multi-modal insights to effectively support early-stage decision making. In May, Samsung Biologics announced plans to spin off its wholly-owned subsidiary, Samsung Bioepis. Through the financial and legal separation, the company will focus on strengthening its core capabilities as a pure-play CDMO, enhancing customer satisfaction and proactively responding to the industry's greater demands to ultimately maximize corporate value and sustainable growth potential. On the sustainability front, the company released its 2025 ESG report in June, outlining progress in areas including enhanced disclosure standards, an accelerated path to net-zero, and TNFD-aligned risk management. As part of its decarbonization efforts, Samsung Biologics achieved a 24% reduction in greenhouse gas emissions in 2024 compared to the previous year and increased its renewable energy use to 29% of total electricity consumption. The company also signed an additional solar Power Purchase Agreement to further support its energy transition. Beyond operations, Samsung Biologics is actively engaged in collaborative efforts through the Sustainable Market Initiative to decarbonize healthcare supply chains and promote global environmental responsibility. About Samsung Biologics Samsung Biologics (KRX: is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 784 kL across five plants, Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. Samsung Biologics operates a global network with facilities and offices in Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo sales office serves the APAC region. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality products, as well as making sustainable business decisions for the betterment of society and global health.
